Full Press Release Details
Investor & Press Contact:
Organovo Holdings, Inc.
ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY REPORTS FISCAL SECOND-QUARTER 2019 RESULTS
- Pre-Investigational New Drug ("IND") meeting with the FDA expected to be held in calendar 2019
- Second orphan designation anticipated in first half of calendar 2019
- Submit first IND in calendar 2020
SAN DIEGO - November 8, 2018 - Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today affirmed its key clinical development goals and reported its fiscal second-quarter 2019 financial results.
"During the fiscal second quarter, we affirmed our key clinical development and operating goals," said Taylor J. Crouch, CEO, Organovo. "We remain on track for a pre-IND meeting with the FDA for our lead indication in calendar 2019 and expect to begin our IND-enabling toxicity study to support multiple orphan disease indications in the second half of calendar 2019. In addition, we plan to conduct proof-of-concept animal studies in multiple rare diseases. We've also made strong progress in pursuing a second orphan designation, and anticipate we'll now receive a response from the FDA in the first half of calendar 2019."
Crouch continued, "We continue to generate favorable preclinical results in our liver therapeutic tissues program and will present data at next week's Liver Meeting on the performance of our tissues in an animal model of hereditary tyrosinemia Type 1 ("HT-1"). This rare disease is often characterized by severe liver damage and limited treatment options. In early studies in established animal models for HT-1, our tissues demonstrated engraftment, retention and functionality post-implantation, while also showing an improvement in the median survival rate for treated animals. Much like with Alpha-1 antitrypsin deficiency ("A1AT"), the same healthy
tissue construct allows us to potentially treat a broad range of target indications. Our objective in implanting a healthy tissue patch is to restore function or offset the deficiency of a specific enzyme abnormality. Our ultimate goal, which we hope to evaluate in future studies, is delaying or reducing the need for a transplant."
Crouch concluded, "We also continue to build upon our cell and in vitro tissue platform, including the launch of a new RNASeq data library by our Samsara division, and several custom projects for our liver tissue research services including disease modeling and toxicology."
Key Clinical Development Goals & Outlook
Fiscal Second-Quarter 2019 Financial Highlights
Definitions & Supplemental Financial Measures
Conference Call Information
As previously announced, the Company will host a conference call to discuss its results at 5:00 p.m. ET on Thursday, November 8, 2018. Callers should dial (888) 317-6003 (U.S. only) or (412) 317-6061 (from outside the U.S.) to access the call. The conference call ID is 2924727. The conference call will also be simultaneously webcast on Organovo's Investor Relations webpage at www.organovo.com. A replay of the conference call will be available beginning Thursday, November 8, 2018 through Thursday, November 15, 2018 at Organovo's Investor Relations webpage. Callers can also dial (877) 344-7529 (U.S. only) or (412) 317-0088, Access Code 10124086, for an audio replay of the conference call.
About Organovo Holdings, Inc.
Organovo is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. The Company is pursuing multiple IND-track programs to develop its NovoTissues to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Organovo's first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA, and the Company expects to file its first IND in 2020. In order to support its plan to initiate multiple IND-track programs, the Company is providing access to its ExVive in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovo's wholly-owned subsidiary, Samsara Sciences, provides the Company and its clients with high quality human liver and kidney cells for research applications. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the potential benefits and therapeutic uses of the Company's therapeutic liver tissue, including the benefits of an orphan designation; the Company's expectations regarding the FDA regulatory pathway and anticipated timelines for its regulatory filings; the potential market opportunity for the Company's therapeutic tissue candidates; the Company's ability to meet market demand; and customer demand for and acceptance of its disease modeling and other in vitro tissue platforms. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the possibility that the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; the Company may not be able to obtain sufficient raw materials to meet market demand for its therapeutic products; risks that competitive products may adversely impact the market opportunity for the Company's therapeutic tissue candidates; the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company's ability to execute framework agreements involving multi-year commitments and routine use on a timely basis, or at all; the Company's ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to recognize deferred revenue; and the Company's ability to meet its fiscal-year 2019 goals and outlook. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2018. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Organovo Holdings, Inc.
Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss
(in thousands except share and per share data)
| Three Months Ended | Three Months Ended | Six Months Ended | Six Months Ended | |||||||||||||
| September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | |||||||||||||
| Revenues | ||||||||||||||||
| Products and services | $ | 493 | $ | 946 | $ | 1,039 | $ | 1,890 | ||||||||
| Collaborations and licenses | 42 | 260 | 85 | 306 | ||||||||||||
| Grants | 408 | 149 | 508 | 149 | ||||||||||||
| Total Revenues | 943 | 1,355 | 1,632 | 2,345 | ||||||||||||
| Cost of revenues | 125 | 254 | 245 | 555 | ||||||||||||
| Research and development expenses | 3,187 | 4,944 | 6,566 | 9,977 | ||||||||||||
| Selling, general and administrative expenses | 3,640 | 5,736 | 8,407 | 11,592 | ||||||||||||
| Total costs and expenses | 6,952 | 10,934 | 15,218 | 22,124 | ||||||||||||
| Loss from Operations | (6,009 | ) | (9,579 | ) | (13,586 | ) | (19,779 | ) | ||||||||
| Other Income (Expense) | ||||||||||||||||
| Gain (loss) on fixed asset disposals | - | - | 2 | - | ||||||||||||
| Interest income | 172 | 118 | 334 | 216 | ||||||||||||
| Total Other Income | 172 | 118 | 336 | 216 | ||||||||||||
| Income Tax Expense | - | - | (3 | ) | - | |||||||||||
| Net Loss | $ | (5,837 | ) | $ | (9,461 | ) | $ | (13,253 | ) | $ | (19,563 | ) | ||||
| Currency Translation Adjustment | $ | - | $ | - | $ | - | $ | (11 | ) | |||||||
| Comprehensive Loss | $ | (5,837 | ) | $ | (9,461 | ) | $ | (13,253 | ) | $ | (19,574 | ) | ||||
| Net loss per common share-basic and diluted | $ | (0.05 | ) | $ | (0.09 | ) | $ | (0.12 | ) | $ | (0.19 | ) | ||||
| Weighted average shares used in computing net loss per common share-basic and diluted | 113,993,237 | 106,297,699 | 112,732,767 | 105,497,939 |
Organovo Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands except for share data)
| September 30, 2018 | March 31, 2018 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 37,355 | $ | 43,726 | ||||
| Accounts receivable | 475 | 883 | ||||||
| Grant receivable | 453 | 145 | ||||||
| Inventory, net | 1,036 | 842 | ||||||
| Prepaid expenses and other current assets | 798 | 1,164 | ||||||
| Total current assets | 40,117 | 46,760 | ||||||
| Fixed assets, net | 2,236 | 2,788 | ||||||
| Restricted cash | 127 | 127 | ||||||
| Other assets, net | 145 | 152 | ||||||
| Total assets | $ | 42,625 | $ | 49,827 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 449 | $ | 464 | ||||
| Accrued expenses | 2,026 | 3,341 | ||||||
| Deferred revenue | 619 | 668 | ||||||
| Deferred rent | 197 | 185 | ||||||
| Total current liabilities | 3,291 | 4,658 | ||||||
| Deferred revenue, net of current portion | - | 19 | ||||||
| Deferred rent, net of current portion | 464 | 564 | ||||||
| Total liabilities | 3,755 | 5,241 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' Equity | ||||||||
| Common stock, $0.001 par value; 200,000,000 shares authorized, 115,200,421 and 111,032,957 shares issued and outstanding at September 30, 2018 and March 31, 2018, respectively | 115 | 111 | ||||||
| Additional paid-in capital | 286,128 | 278,595 | ||||||
| Accumulated deficit | (247,373 | ) | (234,120 | ) | ||||
| Total stockholders' equity | 38,870 | 44,586 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 42,625 | $ | 49,827 |
Organovo Holdings, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
| Six Months Ended | Six Months Ended | |||||||
| September 30, 2018 | September 30, 2017 | |||||||
| Cash Flows From Operating Activities | ||||||||
| Net loss | $ | (13,253 | ) | $ | (19,563 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| (Gain) loss on disposal of fixed assets | (2 | ) | - | |||||
| Depreciation and amortization | 570 | 647 | ||||||
| Stock-based compensation | 2,553 | 4,350 | ||||||
| Increase (decrease) in cash resulting from changes in: | ||||||||
| Accounts receivable | 408 | (386 | ) | |||||
| Grants receivable | (308 | ) | (149 | ) | ||||
| Inventory | (194 | ) | 54 | |||||
| Prepaid expenses and other assets | 366 | 210 | ||||||
| Accounts payable | (15 | ) | (694 | ) | ||||
| Accrued expenses | (1,315 | ) | (1,280 | ) | ||||
| Deferred revenue | (68 | ) | 81 | |||||
| Deferred rent | (88 | ) | (72 | ) | ||||
| Net cash used in operating activities | (11,346 | ) | (16,802 | ) | ||||
| Cash Flows From Investing Activities | ||||||||
| Purchases of fixed assets | (11 | ) | (56 | ) | ||||
| Proceeds from disposals of fixed assets | 2 | - | ||||||
| Purchases of intangible assets | - | (70 | ) | |||||
| Net cash used in investing activities | (9 | ) | (126 | ) | ||||
| Cash Flows From Financing Activities | ||||||||
| Proceeds from issuance of common stock and exercise of warrants, net | 5,129 | 4,135 | ||||||
| Employee taxes paid related to net share settlement of equity awards | (145 | ) | (51 | ) | ||||
| Proceeds from exercise of stock options | - | 825 | ||||||
| Net cash provided by financing activities | 4,984 | 4,909 | ||||||
| Net decrease in cash, cash equivalents, and restricted cash | (6,371 | ) | (12,019 | ) | ||||
| Cash, cash equivalents, and restricted cash at beginning of period | 43,853 | 62,878 | ||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 37,482 | $ | 50,859 | ||||
| Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets | ||||||||
| Cash and cash equivalents | 37,355 | 50,732 | ||||||
| Restricted cash | 127 | 127 | ||||||
| Total cash, cash equivalent and restricted cash | 37,482 | 50,859 | ||||||
| Supplemental Disclosure of Cash Flow Information: | ||||||||
| Income taxes paid | $ | 3 | $ | - |